Remove 2012 Remove FDA Remove Governance Remove Licensing
article thumbnail

Unlocking the mRNA Platform Technology: Walking the Talk with Investment Protection

Bill of Health

By Aparajita Lath Two articles published last month in the BMJ analyze the public investment and financing of mRNA COVID-19 vaccines, highlighting the extensive government funding that has supported the development of mRNA technology from 1985 to 2022. government. government substantially de-risking the vaccine development process.

article thumbnail

Suing the Certifiers – A Dangerous Undertaking

Drug & Device Law

For qualified IMGs, it issues a certification, which IMGs can then use to apply to residency and other graduate medical education programs and to apply for state medical licenses. Furthermore, trade associations often serve to assist the government in areas that it does not regulate. 2012 WL 3265002, at *5 (N.D. Sizemore v.

Doctors 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

D. Arizona Precludes Pelvic Mesh Punitive Damages

Drug & Device Law

As you must know by now, the pelvic mesh MDL court ruled that the FDA 510(k) regulatory clearance of pelvic mesh devices was irrelevant because such clearance was not probative of safety. The Arizona legislature passed the punitive damages exemption statute in August of 2012. Hence, the statute applied.

FDA 69
article thumbnail

NPP, DCC, And FDA-Regulated Medical Products

Drug & Device Law

We are not looking do either of those, but we will weigh in on what NPP means for non-product liability cases involving FDA-regulated medical products. Both talk a fair amount about “commerce” and the respective roles of the states and federal government. Are we down to talk about NPP and its impact on reproductive rights litigation?

FDA 59